Serotonin Geri Emilim Blokörlerinin Hemoreolojik Parametreler Üzerine Etkileri
Özet
Serotonin reuptake inhibitors (SSRI) are widely prescribed drugs for the therapy of major depression. SSRIs both effect on the synaptic level and increase blood serotonin level acutely. There are no detailed studies focusing on the effect of this rise of serotonin in blood and SSRI medication on major parameters determining blood viscosity. This study was planned to assess the effects of SSRIs and serotonin on hemorheological parameters: hematocrit, erythrocyte deformability, erythrocyte aggregation and plasma viscosity. Blood specimens from 10 healthy male individuals were incubated with 40, 60 and 80nM of serotonin for 24 hour. For the investigation of SSRIs, sertraline and fluvoxamine were given to male Sprague-Dawley rats for 5 and 21 days in order to assess their acute and chronic effects. Erythrocyte deformability and erythrocyte aggregation were measured with LORCA device. Plasma viscosity was measured at 900 s-1 shear rate by cone-plate viscometer. All measurements were performed at 37 °C. Plasma serotonin in human and biochemical values reflecting oxidative/antioxidative status in rats were determined. One-way ANOVA, Kruskal-Wallis and Mann-Whitney U Tests were used. In animal experiments SSRIs lower aggregation amplitude in acute fluvoxamine and chronical sertraline groups significantly. They also increased aggregation speed significantly in chronical fluvoxamine group. Biochemical results revealed that SSRI administration caused oxidative stress on rat blood. Serotonin didn?t produce a significant alteration on human blood however aggregation results from human blood resemble outcomes of animal experiments. SSRI administration decreased erythrocyte aggregation amplitude which is a hemorheological parameter. Effect of oxidative stress seems to be related with rise in plasma serotonin level. However no such relation was observed for hemorheological alterations. No concomitant negative effect on hemorheological parameters was observed in this study. It is not possible to evaluate the extent of impact of decrease in aggregation amplitude on blood viscosity with obtained data. Further studies including human subjects with SSRI administration is needed inorder to evaluate the issue for the effects of SSRIs on erythrocyte aggregation and blood viscosity and for the assessment of those possible effects for their impact on cardiovascular complications.